tetano
Editor, Senior Moderator
Jpn J Infect Dis
. 2023 Sep 29.
doi: 10.7883/yoken.JJID.2023.175. Online ahead of print. Difference in the Dynamics of Antibody Titer between COVID-19 Vaccination and SARS-CoV-2 Infection in Healthcare Workers -A Case Study Based on Long-Term and Dense Measurement of Antibody Titer
Hirotaka Tanaka[SUP] 1 [/SUP], Hiroyuki Sawatari[SUP] 2 [/SUP], Shin-Ichi Ando[SUP] 3 [/SUP]
Affiliations
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is prevalent worldwide, and effective and safe vaccines against the virus have been developed. Although trends in antibody titers after vaccination and/or SARS-CoV-2 infection have been reported, the length and frequency of the measurements are limited. This case report describes the long-term and detailed trends in the anti-SARS-CoV-2 S protein receptor-binding domain (S-RBD), repeatedly measured after vaccination and/or infection in three healthcare workers. All healthcare workers received 30 μg of the mRNA vaccine, BNT162b2, during all vaccinations. The peak value of the SARS-CoV-2 S-RBD titer reached at 1-2 week(s) after vaccination, decreased by half within 8 weeks after the vaccination, and the peak values of the antibody titer increased with repeated vaccinations. In contrast, after SARS-CoV-2 infection, the peak value of the antibody titer reached at 4-8 weeks after the infection, but the elevated antibody titer remained up to 16 and 40 weeks after the peak. The present case report shows long-term and detailed trends of SARS-CoV-2 S-RBD titer, with different patterns after vaccination and/or SARS-CoV-2 infection.
Keywords: COVID-19; SARS-CoV-2; antibody titer; infection; vaccination.
. 2023 Sep 29.
doi: 10.7883/yoken.JJID.2023.175. Online ahead of print. Difference in the Dynamics of Antibody Titer between COVID-19 Vaccination and SARS-CoV-2 Infection in Healthcare Workers -A Case Study Based on Long-Term and Dense Measurement of Antibody Titer
Hirotaka Tanaka[SUP] 1 [/SUP], Hiroyuki Sawatari[SUP] 2 [/SUP], Shin-Ichi Ando[SUP] 3 [/SUP]
Affiliations
- PMID: 37779029
- DOI: 10.7883/yoken.JJID.2023.175
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is prevalent worldwide, and effective and safe vaccines against the virus have been developed. Although trends in antibody titers after vaccination and/or SARS-CoV-2 infection have been reported, the length and frequency of the measurements are limited. This case report describes the long-term and detailed trends in the anti-SARS-CoV-2 S protein receptor-binding domain (S-RBD), repeatedly measured after vaccination and/or infection in three healthcare workers. All healthcare workers received 30 μg of the mRNA vaccine, BNT162b2, during all vaccinations. The peak value of the SARS-CoV-2 S-RBD titer reached at 1-2 week(s) after vaccination, decreased by half within 8 weeks after the vaccination, and the peak values of the antibody titer increased with repeated vaccinations. In contrast, after SARS-CoV-2 infection, the peak value of the antibody titer reached at 4-8 weeks after the infection, but the elevated antibody titer remained up to 16 and 40 weeks after the peak. The present case report shows long-term and detailed trends of SARS-CoV-2 S-RBD titer, with different patterns after vaccination and/or SARS-CoV-2 infection.
Keywords: COVID-19; SARS-CoV-2; antibody titer; infection; vaccination.